The technology enables a cost-effective and commercially scalable nanowire biosensor for near-patient or point-of-care patient testing with real-time electric sensing of multiple target markers in a single sample. Qualitative and quantitative tests can be performed from a single-use biosensor chip embedded in a disposable test cartridge. No PCR or tag molecule (i.e. radioactive isotope, fluorophore, magnetic beads, enzyme, etc.) is needed.
"The granting of this patent is a critical accomplishment in recognition of the unique qualities of NanoIVD’s nanowire biosensor technology, said Sunnie Park Kim, NanoIVD’s Chief Executive Officer. Kim added, “Because early detection can improve the cure rate and quality-of-life for cancer patients, bravely fighting the battle, the biosensor is an important milestone achievement for NanoIVD and serves as springboard for commercial development of simple blood tests that quantitatively measures key biomarkers of cancer pathways and progression identified by NanoIVD’s algorithm from thousands of clinical data.”
NanoIVD’s pancreatic, liver, thyroid, prostate, and other cancer tests are intended to aid healthcare professionals in:
• appropriate treatment selection that reduces patient risk and increases effectiveness
• estimated patient prognosis and treatment management
• detection and diagnosis before cancer symptoms occur
In addition to cancer, the nanowire biosensor technology can be used for testing a variety of other conditions such as Alzheimer’s, diabetes, and coronary artery diseases, as well as infectious diseases; interestingly NanoIVD’s research on cancer pathways also revealed significant effects to genes for insulin receptor, insulin, apolipoprotein B (associated with coronary heart disease), and amyloid (Alzheimer’s disease).
NanoIVD is a nonpublic Delaware C corporation established in November 2008. The company actively works on new discoveries and innovations. The company has proprietary technologies for a point-of-care analyzer and single-use test cartridge system capable of minimally invasive health monitoring, early disease detection, and treatment-effectiveness monitoring using small amounts of blood. The technologies can achieve high sensitivity and specificity—
NanoIVD is headquartered at Good Samaritan Hospital Medical Building (Los Angeles, CA). It also utilizes the California NanoSystems Institute (CNSI) at UCLA, Nanoelectronics Research Facility (NRF) at UCLA, and the Kavli Nanoscience Institutes (KNI) at Caltech.
Statements about our future expectations, including development and regulatory plans, and all other statements in this press release, other than historical facts, are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "may," "will," "should," "anticipate,"
Direct inquiries to: